A subscription to JoVE is required to view this content. Sign in or start your free trial.

Method Article

CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors

7.7K views

⸱

DOI:

10.3791/59432

⸱

September 14th, 2019

 ,  ,  ,  , 

In This Article

Summary

Here, we present a Cas9-based exon23 deletion protocol to restore dystrophin expression in iPSC from Dmdmdx mouse-derived skin fibroblasts and directly differentiate iPSCs into myogenic progenitor cells (MPC) using the Tet-on MyoD activation system.

Abstract

Duchenne muscular dystrophy (DMD) is a severe progressive muscle disease caused by mutations in the dystrophin gene, which ultimately leads to the exhaustion of muscle progenitor cells. Clustered regularly interspaced short palindromic repeats/CRISPR-associated 9 (CRISPR/Cas9) gene editing has the potential to restore the expression of the dystrophin gene. Autologous induced pluripotent stem cells (iPSCs)-derived muscle progenitor cells (MPC) can replenish the stem/progenitor cell pool, repair damage, and prevent further complications in DMD without causing an immune response. In this study, we introduce a combination of CRISPR/Cas9 and non-integrated iPSC technologies to obtain muscle progenitors with recovered dystrophin protein expression. Briefly, we use a non-integrating Sendai vector to establish an iPSC line from dermal fibroblasts of Dmdmdx mice. We then use the CRISPR/Cas9 deletion strategy to restore dystrophin expression through a non-homologous end joining of the reframed dystrophin gene. After PCR validation of exon23 depletion in three colonies from 94 picked iPSC colonies, we differentiate iPSC into MPC by doxycycline (Dox)-induced expression of MyoD, a key transcription factor playing a significant role in regulating muscle differentiation. Our results show the feasibility of using CRISPR/Cas9 deletion strategy to restore dystrophin expression in iPSC-derived MPC, which has significant potential for developing future therapies for the treatment of DMD.

Introduction

Duchenne muscular dystrophy (DMD) is one of the most common muscular dystrophies and is characterized by the absence of dystrophin, affecting 1 of approximately 5,000 newborn boys worldwide1. Loss of dystrophin gene function results in structural muscle defects leading to progressive myofibers degeneration1,2. Recombinant adeno-associated virus (rAAV)-mediated gene therapy system has been tested to restore the dystrophin expression and improve muscle function, such as gene replacement using micro-dystrophins (µ-Dys). However, the rAAV approach requires repeated injections to sustai....

Access restricted. Please log in or start a trial to view this content.

Protocol

All animal handling and surgical procedures were performed by a protocol approved by the Augusta University Institutional Animal Care and Use Committee (IACUC). Mice were fed standard diet and water ad libitum.

1. Isolation of primary mouse fibroblasts from adult Dmdmdx mice

  1. Euthanize adult Dmdmdx mice (male, 2 months old) by CO2 asphyxiation and thoracotomy according to IACUC approved by Medical College of Georgia, Augusta University. Cut the tail with a sterile scalpel in a sterile condition under the laminar hood. Rinse the tail with 70% ethanol for 5 min, and then wash with sterile phosphate-b....

Access restricted. Please log in or start a trial to view this content.

Results

Establishment of Dmdmdx skin fibroblasts derived iPSC. We demonstrated the efficiency of generating mouse iPSCs from Dmdmdx mice derived skin fibroblast using the integration-free reprogramming vectors. Figure 1A demonstrated that the appearance of embryonic stem cell (ESC)-like colonies at three weeks after infection. We evaluate the efficiency of iPSC induction by live alkaline phosphatase (AP) stain; Figure 1B s.......

Access restricted. Please log in or start a trial to view this content.

Discussion

Duchenne Muscular Dystrophy (DMD) is a destructive and ultimately fatal hereditary disease characterized by a lack of dystrophin, leading to progressive muscle atrophy1,2. Our results demonstrate the restored dystrophin gene expression in Dmdmdx iPSC-derived myogenic progenitor cells by the approach of CRISPR/Cas9-mediated exon23 deletion. This approach has three advantages.

First, we generated iPSCs from Dmdmdx m.......

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

Tang and Weintraub were partially supported by NIH-AR070029, NIH-HL086555, NIH-HL134354.

....

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
Surgical Instruments
31-gauge needleVarious 
Sharp IncisionVarious 
Sterile ScalpelsVarious 
TweezersVarious 
Fibroblast medium (for 100 mL of complete medium)CompanyCatalog NumberVolume
2-Mercaptoethanol (55 mM)Gibco21-985-0230.1 mL
Antibiotic Antimycotic Slution 100xCORNINGMT30004CI1 mL
Dulbecco's Modified Eagle's Medium - high glucoseSIGMAD642987 mL
Fetal Bovine Serum CharacterizedHyCloneSH30396.0310 mL
L-Glutamine solutionSIGMAG75131 mL
MEM Non-Essential Amino Acids Solution (100x) Gibco111400761 mL
TVP solution (for 500 mL of complete solution)CompanyCatalog NumberVolume
Chicken SerumGibco16110-0825 mL
EDTASigma-AldrichE6758186 mg
Phosphat-buffered salineto 500 mL
Trypsin (2.5%)Thermo150900465 mL
mES growth medium(for 500 mL of complete solution)CompanyCatalog NumberVolume
2-Mercaptoethanol (55 mM)Gibco21-985-0230.5 mL
Antibiotic Antimycotic Slution 100xCORNINGMT30004CI5 mL
Dulbecco's Modified Eagle's Medium - high glucoseSIGMAD6429408.5 mL
Fetal Bovine Serum CharacterizedHyCloneSH30396.0375 mL
L-Glutamine solutionSIGMAG75135 mL
Mouse recombinant Leukemia Inhibitory Factor (LIF), 0.5 x 106 U/mLEMD Millipore CorpCS210511500 μL
MEK/GS3 Inhibitor SupplementEMD Millipore CorpCS210510-500UL500 μL
MEM Non-Essential Amino Acids Solution (100x) Gibco111400765 mL
The ES cell media should not be stored for more than 4 weeks and with inhibitors not more than 2 weeks.
mES frozen medium(for 50 mL of complete solution)CompanyCatalog NumberVolume
Dimethyl sulfoxide (DMSO)SIGMAD26505 mL
Dulbecco's Modified Eagle's Medium - high glucoseSIGMAD642924.9 mL
Fetal Bovine Serum CharacterizedHyCloneSH30396.0325 mL
Mouse recombinant Leukemia Inhibitory Factor (LIF), 0.5 x 106 U/mLEMD Millipore CorpCS21051150 μL
Name of Material/ EquipmentCompanyCatalog NumberRRID
0.05% Trypsin/0.53 mM EDTACORNING25-052-CI
4% ParaformaldehydeThermo scientificJ19943-k2
Accutase solutionSIGMAA6964Cell detachment solution
AgeI-HFNEBR3552L
Alexa488-conjugated goat-anti-mouse antibodyInvitrogenA32723AB_2633275
Alexa488-conjugated goat-anti-rabbit antibodyInvitrogenA32731AB_2633280
Alexa555-conjugated goat-anti-rabbit antibodyInvitrogenA32732AB_2633281
anti-AFPThermo scientificRB-365-A1AB_59574
anti-α-Smooth Muscle Actin (D4K9N) XPCST19245SAB_2734735
anti-DystrophinThermoPA5-32388AB_2549858
anti-LIN28A (D1A1A) XP   CST8641SAB_10997528
anti-MYH2DSHBmAb2F7AB_1157865
anti-Nanog-XPCST8822SAB_11217637
anti-Oct-4A (D6C8T)CST83932SAB_2721046
anti-Sox2abcamab97959AB_2341193
anti-SSEA1(MC480) CST4744sAB_1264258
anti-TH (H-196)SANTA CRUZ sc-14007AB_671397
Alkaline Phosphatase Live Stain (500x)ThermoA14353
Blasticidin SSigma-Aldrich203350
BsmBI/Esp3INEBR0580L/R0734L
CarbenicillinMillipore205805-250MG
Collagenase IV Worthington Biochemical CorporationLS004189
Competent CellsTakaRa636763
CutSmart NEBB7204S
CytoTune-iPS 2.0 Sendai Reprogramming KitThermoA16517
DirectPCR Lysis Reagent (cell)VIAGEN BIOTECH302-C
Dispase (1 U/mL)STEMCELL Technologies7923
Doxycycline HydrochlorideFisher BioReagentsBP26535
EcoRI-HFNEBR3101L
Fibronectin bovine plasmaSIGMAF1141
 
QIAEX II Gel Extraction Kit (500)
QIAGEN20051
Gelatin from porcine skin, type ASIGMAG1890
HardSet Antifade Mounting Medium with DAPIVectorH-1500
Hygromycin B (50 mg/mL)Invitrogen10687010
Ketamine HCL InjectionHENRY SCHEIN ANIMAL HEALTH45822
KpnI-HFNEBR3142L
lenti-CRISPRv2-blastAddgene83480
lenti-Guide-Hygro-iRFP670Addgene99377
Lipofectamin 3000 Transfection KitInvitrogenL3000015
LV-TRE-VP64-mouse MyoD-T2A-dsRedExpress2  Addgene60625
LV-TRE-VP16 mouse MyoD-T2A-dsRedExpress2Addgene60626
Mouse on Mouse (M.O.M.) Basic KitVectorBMK-2202
NotI-HFNEBR3189L
Opti-MEM I Reduced Serum MediaThermoFisher31985070
Polyethylene glycol 4,000Alfa AesarAAA161510B
PolybreneSIGMATR1003
Corning BioCoat Poly-D-Lysine/Laminin Culture SlideCORNINGCB354688
PowerUp SYBR Green Master MixThermoFisherA25742
PrimeSTAR Max PremixTakaRaR045
Proteinase KVIAGEN BIOTECH507-PKP
Puromycin DihydrochlorideMP BiomedicalsICN19453980
qPCR Lentivirus Titration KitabmLV900
Quick ligation kitNEBM2200S
QIAprep Spin Miniprep Kit (250)QIAGEN27106
QIAGEN Plasmid Plus Midi Kit (100)QIAGEN12945
RevertAid RT Reverse Transcription KitThermo scientificK1691
RNAzol RTMolecular Research Center, INCRN 190
T4 DNA Ligase Reaction BufferNEBB0202S
T4 Polynucleotide KinaseNEBM0201S
Terrific Broth ModifiedFisher BioReagentsBP9729-600
ViralBoost Reagent (500x)ALSTEMVB100

References

  1. Mendell, J. R., et al. Evidence-based path to newborn screening for Duchenne muscular dystrophy. Annals of Neurology. 71 (3), 304-313 (2012).
  2. Batchelor, C. L., Winder, S. J. Sparks, signals and shock absorbers: how dystrophin loss cause....

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Explore More Articles

CRISPR/Cas9 Gene EditingDystrophin Expression RestorationDuchenne Muscular DystrophyNon-Homologous End JoiningExon23 DeletionMyoD-Induced DifferentiationSendai Vector ReprogrammingPCR ValidationAgarose Gel Electrophoresis